User login
SAN FRANCISCO – In the United States, deaths from cardiovascular disease fell by about 50% in men and women between 1980 and 2000, and fell an additional 31% between 2000 and 2010, according to Robert Baron, MD.
That’s the good news, driven largely by the introduction of statin therapy and by risk-factor modifications. The not-so-great news? The optimal screening age for CVD risk remains elusive.
“We’ve been arguing about this for at least 30 years,” he said at the UCSF Annual Advances in Internal Medicine.
The 2013 American College of Cardiology/American Heart Association Guideline on the Assessment of Cardiovascular Risk recommends screening at age 21 years to identify those with an LDL cholesterol level greater than 190 mg/dL, while a more recent draft recommendation statement from the United States Preventive Services Task Force (USPSTF) recommends screening at age 35 in men and 45 in women for most cases, or at age 20 in people deemed to be at increased risk. Both sets of guidelines recommend the use of statins in patients with atherosclerotic cardiovascular disease, and LDL of 190 mg/dL or greater, and/or diabetes.
“In essence, the USPSTF guidelines are saying definitely use statins for primary prevention in high-risk people; they’re just creating a little more gray area as to what exactly constitutes high risk,” said Dr. Baron, an internist who is associate dean at UCSF Medical Center, San Francisco. “The question is, how do you draw the line? I would argue that depends on the patient preference.”
In a recently published analysis, researchers set out to determine how the USPSTF guidelines compare with the ACC/AHA guidelines in terms of the proportion of U.S. adults potentially treated (JAMA. 2017 Apr 18; 317[15]:1563-7). After using estimates based on data from 3,416 participants in the 2009-2014 National Health and Nutrition Examination Survey, the researchers found that USPSTF recommendations would be associated with statin initiation in 16% of U.S. adults aged 40-75 years without prior CVD, compared with 24% according to the ACC/AHA guidelines.
Among those adults for whom therapy would no longer be recommended under the USPSTF recommendations, 55% are aged 40-59 years with a mean 30-year cardiovascular risk exceeding 30%, and 28% have diabetes. According to Dr. Baron, the comparison “reinforces the primary prevention message. It gives the patient a bit more flexibility.”
After starting patients on a statin, the best available evidence recommends monitoring adherence but not treating to a specific LDL goal, he said. Statins should not be used in patients older than age 75 unless they have existing ASCVD. The addition of other lipid-modifying drugs is generally not recommended, but it may be needed in patients who demonstrate intolerance to statins. Patients should also avoid using NSAIDS, which raise CVD risk, and instead use medications that lower it, such as aspirin, he said.
Dr. Baron reported having no relevant financial disclosures.
SAN FRANCISCO – In the United States, deaths from cardiovascular disease fell by about 50% in men and women between 1980 and 2000, and fell an additional 31% between 2000 and 2010, according to Robert Baron, MD.
That’s the good news, driven largely by the introduction of statin therapy and by risk-factor modifications. The not-so-great news? The optimal screening age for CVD risk remains elusive.
“We’ve been arguing about this for at least 30 years,” he said at the UCSF Annual Advances in Internal Medicine.
The 2013 American College of Cardiology/American Heart Association Guideline on the Assessment of Cardiovascular Risk recommends screening at age 21 years to identify those with an LDL cholesterol level greater than 190 mg/dL, while a more recent draft recommendation statement from the United States Preventive Services Task Force (USPSTF) recommends screening at age 35 in men and 45 in women for most cases, or at age 20 in people deemed to be at increased risk. Both sets of guidelines recommend the use of statins in patients with atherosclerotic cardiovascular disease, and LDL of 190 mg/dL or greater, and/or diabetes.
“In essence, the USPSTF guidelines are saying definitely use statins for primary prevention in high-risk people; they’re just creating a little more gray area as to what exactly constitutes high risk,” said Dr. Baron, an internist who is associate dean at UCSF Medical Center, San Francisco. “The question is, how do you draw the line? I would argue that depends on the patient preference.”
In a recently published analysis, researchers set out to determine how the USPSTF guidelines compare with the ACC/AHA guidelines in terms of the proportion of U.S. adults potentially treated (JAMA. 2017 Apr 18; 317[15]:1563-7). After using estimates based on data from 3,416 participants in the 2009-2014 National Health and Nutrition Examination Survey, the researchers found that USPSTF recommendations would be associated with statin initiation in 16% of U.S. adults aged 40-75 years without prior CVD, compared with 24% according to the ACC/AHA guidelines.
Among those adults for whom therapy would no longer be recommended under the USPSTF recommendations, 55% are aged 40-59 years with a mean 30-year cardiovascular risk exceeding 30%, and 28% have diabetes. According to Dr. Baron, the comparison “reinforces the primary prevention message. It gives the patient a bit more flexibility.”
After starting patients on a statin, the best available evidence recommends monitoring adherence but not treating to a specific LDL goal, he said. Statins should not be used in patients older than age 75 unless they have existing ASCVD. The addition of other lipid-modifying drugs is generally not recommended, but it may be needed in patients who demonstrate intolerance to statins. Patients should also avoid using NSAIDS, which raise CVD risk, and instead use medications that lower it, such as aspirin, he said.
Dr. Baron reported having no relevant financial disclosures.
SAN FRANCISCO – In the United States, deaths from cardiovascular disease fell by about 50% in men and women between 1980 and 2000, and fell an additional 31% between 2000 and 2010, according to Robert Baron, MD.
That’s the good news, driven largely by the introduction of statin therapy and by risk-factor modifications. The not-so-great news? The optimal screening age for CVD risk remains elusive.
“We’ve been arguing about this for at least 30 years,” he said at the UCSF Annual Advances in Internal Medicine.
The 2013 American College of Cardiology/American Heart Association Guideline on the Assessment of Cardiovascular Risk recommends screening at age 21 years to identify those with an LDL cholesterol level greater than 190 mg/dL, while a more recent draft recommendation statement from the United States Preventive Services Task Force (USPSTF) recommends screening at age 35 in men and 45 in women for most cases, or at age 20 in people deemed to be at increased risk. Both sets of guidelines recommend the use of statins in patients with atherosclerotic cardiovascular disease, and LDL of 190 mg/dL or greater, and/or diabetes.
“In essence, the USPSTF guidelines are saying definitely use statins for primary prevention in high-risk people; they’re just creating a little more gray area as to what exactly constitutes high risk,” said Dr. Baron, an internist who is associate dean at UCSF Medical Center, San Francisco. “The question is, how do you draw the line? I would argue that depends on the patient preference.”
In a recently published analysis, researchers set out to determine how the USPSTF guidelines compare with the ACC/AHA guidelines in terms of the proportion of U.S. adults potentially treated (JAMA. 2017 Apr 18; 317[15]:1563-7). After using estimates based on data from 3,416 participants in the 2009-2014 National Health and Nutrition Examination Survey, the researchers found that USPSTF recommendations would be associated with statin initiation in 16% of U.S. adults aged 40-75 years without prior CVD, compared with 24% according to the ACC/AHA guidelines.
Among those adults for whom therapy would no longer be recommended under the USPSTF recommendations, 55% are aged 40-59 years with a mean 30-year cardiovascular risk exceeding 30%, and 28% have diabetes. According to Dr. Baron, the comparison “reinforces the primary prevention message. It gives the patient a bit more flexibility.”
After starting patients on a statin, the best available evidence recommends monitoring adherence but not treating to a specific LDL goal, he said. Statins should not be used in patients older than age 75 unless they have existing ASCVD. The addition of other lipid-modifying drugs is generally not recommended, but it may be needed in patients who demonstrate intolerance to statins. Patients should also avoid using NSAIDS, which raise CVD risk, and instead use medications that lower it, such as aspirin, he said.
Dr. Baron reported having no relevant financial disclosures.
EXPERT ANALYSIS FROM THE ANNUAL ADVANCES IN INTERNAL MEDICINE